Perazin 100 mg

Leaflet attached to the packaging: patient information

PERAZIN 25 mg

25 mg, tablets

Perazinum

PERAZIN 100 mg

100 mg, tablets

Perazinum

You should carefully read the contents of the leaflet before using the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• In case of any doubts, you should consult a doctor, pharmacist, or nurse.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Perazin 25 mg and Perazin 100 mg and what are they used for
• 2. Important information before using Perazin 25 mg and Perazin 100 mg
• 3. How to use Perazin 25 mg and Perazin 100 mg
• 4. Possible side effects
• 5. How to store Perazin 25 mg and Perazin 100 mg
• 6. Contents of the packaging and other information
• 1. What is Perazin 25 mg and Perazin 100 mg and what are they used for

The active substance of Perazin 25 mg and Perazin 100 mg is perazine, which has antipsychotic and sedative effects, and eliminates hallucinations and delusions.
Indications for use arevarious forms of schizophrenia and acute psychotic disorders (including catatonic) with accompanying symptoms of psychomotor agitation, mania, and delusions.
Catonia is a syndrome of symptoms, in which motor disorders dominate, taking the form of either slowing down to inhibition of movements or sudden motor agitation.

2. Important information before using Perazin 25 mg and Perazin 100 mg

When not to use Perazin 25 mg or Perazin 100 mg

• if the patient is allergic to perazine or any of the other ingredients of this medicine (listed in section 6) or other antipsychotic medicines, especially phenothiazine derivatives,
• if the patient has a history of malignant neuroleptic syndrome,
• in case of severe bone marrow damage or blood cell damage,
• if the patient is in a coma,
• during pregnancy and breastfeeding,
• in case of acute poisoning with one of the following substances: sleeping pills, opioids, other neuroleptic medicines, sedatives, antidepressants, alcohol,
• if the patient has prolactin-dependent tumors, due to increased prolactin secretion under the influence of perazine,
• in case of liver failure,
• if the patient has depressive states.

You should consult a doctor, even if the above warnings apply to past situations.

Warnings and precautions

Before starting treatment with Perazin 25 mg or Perazin 100 mg, you should discuss it with your doctor, pharmacist, or nurse.
In case of liver function disorders, the dose should be reduced accordingly (see section 3).
After using the maximum doses, severe liver damage may occur.
Caution should be exercised in patients with renal failure, as phenothiazine derivatives may cause hypotension.
Particular caution should be exercised when treating patients with perazine who have:

• decreased white blood cell count (leukopenia) or other blood system disorders,
• heart muscle damage in their medical history,
• severe hypotension, sudden drop in blood pressure when changing from a lying to a standing position (orthostatic hypotension),
• seizures in their medical history,
• Parkinson's disease,
• glaucoma with a narrow angle of filtration,
• urination disorders, narrowing of the pylorus, prostate hypertrophy,
• excessive motor activity associated with involuntary movements or decreased motor activity, stiffness, and muscle tremors (extrapyramidal system disorders),
• movement disorders, manifested by, among others, choreiform movements (dyskinesia),
• myasthenia gravis (a disease characterized by rapid fatigue and weakness of skeletal muscles),
• active peptic ulcer disease and chronic liver diseases,
• narrowing of the pylorus,
• hyperthyroidism,
• pheochromocytoma of the adrenal gland,
• disorders of new blood cell formation (hematopoiesis),
• acute anemia,
• breast tumors.

During treatment with perazine, it is necessary:

• to constantly monitor blood glucose levels in patients with diabetes,
• to monitor the cardiovascular system: control of blood pressure and observation of possible irregularities in heart function; for this purpose, frequent blood pressure measurements and ECG tests should be performed; this is especially important in elderly patients; ECG monitoring is recommended in patients with heart diseases and defects,
• to perform liver function tests (blood laboratory tests) at the beginning of treatment and then after 6 months.

In case of suspected malignant neuroleptic syndrome, it is recommended to immediately discontinue the medicine and seek medical help as soon as possible. Malignant neuroleptic syndrome, which occurs in individual cases, is characterized by, among other things, an increase in body temperature to 40°C and muscle stiffness.
It is recommended to reduce the dose or discontinue the medicine and immediately perform blood tests if, after using the medicine, the following occur:

• changes in the blood picture (decrease in the number of leukocytes, decrease in the number of platelets),
• nosebleeds,
• disorders of consciousness, accompanied by illusions, visual, auditory, tactile, and other hallucinations (delirium),
• depression,
• skin changes of the type of urticaria or irritation,
• increased liver enzyme activity and jaundice.

In case of significant decrease in the number of leukocytes, as well as changes in the peripheral blood smear, the doctor may decide to discontinue perazine treatment and use another medicine.
During long-term treatment with perazine, blood tests should be performed every 6 months.
In case of movement disorders (early dyskinesia or parkinsonian syndrome) such as choreiform movements, involuntary movements, excessive motor activity, or decreased motor activity, stiffness, and muscle tremors, the doctor may recommend reducing the dose or introducing anti-parkinsonian treatment.
During treatment with perazine, cases of hypersensitivity to light have been reported. It is recommended to avoid intense sunlight and reduce sensitivity to light by using protective creams with UV filters.
The use of perazine may cause skin allergic reactions.

Children and adolescents

There is a lack of sufficient data to assess the safety of using the medicine in children and adolescents under 16 years of age, so perazine is intended only for the treatment of adults.

Elderly patients

Elderly patients should receive reduced doses of perazine. It is recommended to use half of the adult dose. Such dosing usually provides the desired therapeutic effect in elderly patients.

Perazin 25 mg or Perazin 100 mg and other medicines

You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to use.
Administration of perazine together with:

• levodopa causes mutual neutralization of their effects,
• cimetidine causes an increase in the availability of perazine in the body,
• lithium carbonate increases the risk of nervous system damage and increased blood sugar levels,
• beta-adrenergic receptor blockers (lowering blood pressure) may lead to excessive lowering of blood pressure,
• medicines with anticholinergic effects (atropine, trihexyphenidyl) increase the risk of hallucinations, reduce the antipsychotic effect,
• ethanol, sleeping pills, and sedatives increase the sedative effect and the risk of respiratory complications (respiratory paralysis),
• antiepileptic medicines (e.g., phenytoin, carbamazepine) cause a decrease in the antipsychotic effect of perazine, weakening of the anticonvulsant effect,
• oral anticoagulants weaken the anticoagulant effect,
• monoamine oxidase inhibitors and oral contraceptives result in a weakening of the sedative effect of perazine and an increase in the occurring side effects,
• antidiabetic medicines cause a decrease in their effect,
• narcotic analgesics and other painkillers and antipyretics increase their analgesic and sedative effects,
• tricyclic antidepressants (TCA, e.g., imipramine, amitriptyline) cause weaker effects of the medicines (mutual inhibition of uptake of medicines by tissues),
• selective serotonin reuptake inhibitors (SSRI, e.g., fluoxetine, fluvoxamine, sertraline) cause mutual inhibition of uptake of medicines by tissues and a significant increase in the concentration of perazine in the blood,
• medicines that impair bone marrow function (myelotoxic) such as, for example, phenylbutazone, aminophenazone, chloramphenicol, result in an increased risk of bone marrow disorders and changes in the blood picture.

During perazine therapy, false pregnancy test results have been observed.

Using Perazin 25 mg or Perazin 100 mg with alcohol

During treatment with perazine, the patient should not consume products containing alcohol.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks she may be pregnant, or plans to have a child, she should consult a doctor or pharmacist before using this medicine.
Perazine passes through the placental barrier, so the use of the medicine in pregnant women is contraindicated.
Perazine passes into breast milk. If treatment with perazine is necessary, breastfeeding should be discontinued.

Driving vehicles and operating machines

The medicine may cause significant impairment of psychophysical fitness. During treatment with perazine, you should not drive vehicles or operate machines.

Perazin 25 mg contains lactose

If the patient has previously been diagnosed with intolerance to some sugars, they should inform their doctor before taking the medicine.

3. How to use Perazin 25 mg and Perazin 100 mg

This medicine should always be used in accordance with the doctor's or pharmacist's recommendations. In case of doubts, you should consult a doctor or pharmacist.
The medicine is used orally.
Initially, 50 to 100 mg is used per day, and in the further course of treatment, the dose is gradually increased to 300 to 600 mg per day in divided doses. The maximum therapeutic dose is 800 mg per day in divided doses. The maintenance dose is 75 to 300 mg per day.
Treatment of outpatients should be started with the smallest effective doses, and then the dose can be increased until the desired response to treatment is achieved.
Sudden changes in dosage are not recommended, as this increases the risk of side effects.
The maximum antipsychotic effect is achieved after one to three weeks of treatment.

Patients with renal impairment

In renal impairment, there is no need to change the dosage of the medicine.

Patients with liver impairment

In patients with liver function disorders, it is recommended to reduce the doses of perazine. It is recommended to use half of the adult dose, and in severe liver failure, discontinue the medicine.

Patients in old age

Elderly patients should receive reduced doses of the medicine. It is recommended to use half of the adult dose. Such dosing usually provides the desired therapeutic effect in elderly patients.

Use in children and adolescents

There is a lack of sufficient data to assess the safety of using the medicine in children and adolescents under 16 years of age, so perazine is intended only for the treatment of adults.

Using a higher than recommended dose of Perazin 25 mg or Perazin 100 mg

Symptoms
Accidental or intentional overdose (ingestion of several or several dozen grams of perazine) usually manifests as difficulty speaking, clumsiness, vision disturbances, muscle tremors, confusion, cardiac arrest, and circulatory disorders, shortness of breath, and breathing difficulties, as well as disorders of thermoregulation (ability to maintain a constant body temperature).
Procedure after overdose
In case of taking a significantly higher dose of the medicine than recommended, you should immediately consult a doctor or pharmacist.

Missing a dose of Perazin 25 mg or Perazin 100 mg

You should take the missed dose as soon as possible, unless it is already time for the next dose. You should not take a double dose to make up for the missed dose.

Discontinuing Perazin 25 mg or Perazin 100 mg

Treatment of psychotic disorders is long-term. After achieving satisfactory improvement, it is not recommended to reduce the dose of the medicine too quickly. The doses should be reduced gradually over several to several months. Discontinuation of the medicine may only be done under the supervision of a doctor and in accordance with their recommendations.
In case of any further doubts related to the use of this medicine, you should consult a doctor, pharmacist, or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although they may not occur in everyone.
In case of malignant neuroleptic syndrome, characterized by an increase in body temperature to 40°C and muscle stiffness, accompanied by an increase in myoglobin and creatine kinase activity in the blood, you should immediately seek medical help.
Very common(in 1 in 10 patients):
galactorrhea
Common(in 1 to 10 patients in 100):
change in intraocular pressure, swelling of the nasal mucosa, constipation, difficulty urinating, weight gain, dryness of the mucous membranes of the mouth, increased thirst, sexual function disorders (e.g., erection disorders, ejaculation disorders).
Uncommon(in 1 to 10 patients in 1000):
movement disorders (dyskinesia, parkinsonian syndrome) manifested by choreiform movements, involuntary movements, excessive motor activity, or decreased motor activity, stiffness, and muscle tremors, sleep disorders, general restlessness, increased occurrence of nightmares, disorientation, and confusion.
Rare(in 1 to 10 patients in 10,000):
changes in sensation in the hands and feet, seizures, hypersensitivity of the eyes to light, severe hypersensitivity reactions to light, accompanied by pigment deposition, vascular collapse, breast hypertrophy in men, disorders of consciousness, accompanied by illusions, visual, auditory, tactile, and other hallucinations.
Very rare(in less than 1 patient in 10,000):
edema, decrease in granulocyte levels in the blood, extrapyramidal symptoms manifested by inability to remain calm in a sitting position, often accompanied by depression, occurring usually after the manic phase of psychosis, malignant neuroleptic syndrome, occurring in individual cases, respiratory disorders, gastrointestinal disorders, nausea, gangrenous enteritis leading to intestinal necrosis, skin changes of the type of erythema (lupus erythematosus), cholestasis.

Frequency not known

false pregnancy test results, heart rhythm disorders, lowering of blood pressure, decrease in leukocyte count, decrease in platelet count, skin changes of the type of urticaria or irritation, nosebleeds, increased liver enzyme activity, and jaundice, menstrual disorders, breast hypertrophy in women.

Reporting side effects

If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Aleje Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309,
e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help gather more information on the safety of the medicine.

5. How to store Perazin 25 mg and Perazin 100 mg

The medicine should be stored in a place that is invisible and inaccessible to children.
Store at a temperature below 25°C. Store in the original packaging.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste containers. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What does Perazin 25 mg or Perazin 100 mg contain

• The active substance of the medicine is perazine. 1 tablet contains 25 mg or 100 mg of perazine.
• Other ingredients (excipients) are:

Perazin 25 mg
lactose monohydrate, potato starch, methylcellulose, anhydrous colloidal silica, sodium carboxymethylcellulose, magnesium stearate.
Perazin 100 mg
heavy magnesium carbonate, povidon K-30, sodium croscarmellose, magnesium stearate.

What does Perazin 25 mg or Perazin 100 mg look like and what does the packaging contain

Perazin 25 mg is an uncoated, yellow, convex tablet with a smooth surface on both sides.
One packaging of Perazin 25 mg contains 20, 30, or 50 tablets.
Perazin 100 mg is an uncoated, yellow, oval, biconvex tablet with a smooth surface and a dividing line.
One packaging of Perazin 100 mg contains 30 tablets.

Marketing authorization holder and manufacturer

“PRZEDSIĘBIORSTWO PRODUKCJI FARMACEUTYCZNEJ HASCO-LEK” S.A.
51-131 Wrocław, ul. Żmigrodzka 242 E

Information about the medicine

tel. (22) 742 00 22
e-mail: informacjaoleku@hasco-lek.pl

Date of the last update of the leaflet: